Cabozantinib in everyday care for adults with previously treated neuroendocrine tumors
Follows adults with neuroendocrine tumors who take cabozantinib as part of usual care.
Plain-language title generated from the registry record
Registry title: Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
Key facts
- Where
- Graz, Linz, and Vienna, AustriaSee the 3 sites
Where in Austria
- Medizinische Universitaet GrazGraz, AustriaTaking people
- Kepler Universitaetsklinikum GmbH LinzLinz, AustriaNot yet recruiting
- Medizinische Universität WienVienna, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ipsen
- Trial code
- NCT07314164
- Record updated
- 1 October 2026
- Original description
This study will assess how well cabozantinib works and how safe it is in adults with a type of cancer called neuroendocrine tumors (NETs).Read full original descriptionShow less
CaboLife: A Prospective Non-Interventional Study on Effectiveness and Safety of Cabozantinib in Real-Life Setting for Previously Treated Patients With Neuroendocrine Tumour
This study will assess how well cabozantinib works and how safe it is in adults with a type of cancer called neuroendocrine tumors (NETs).
These tumors can appear in all parts of the body. All participants in this study have already received at least one treatment that affects the whole body to help manage their cancer, but their disease has continued to grow.
The study will take place in regular hospitals and clinics in Germany and Austria.
It will follow about 150 participants who are taking cabozantinib as part of their usual care. Doctors will collect information from routine medical visits, tests, and scans to see how the cancer responds to treatment and how long participants stay on cabozantinib. They will also look at side effects and how the treatment affects participants' quality of life.
This is an observational study, which means that no extra tests or procedures will be done beyond what is normally used to care for participants with this condition.
Inclusion: Participants can join the study if they meet all of the following conditions:; Are 18 years or older and able to give informed consent; Have a physician-initiated decision to start treatment with cabozantinib for neuroendocrine tumors (NETs), made before joining the study; Have unresectable or metastatic, well-differentiated pancreatic (pNET) or extra-pancreatic neuroendocrine tumors (epNET); Have already received at least one prior systemic therapy, other than somatostatin analogues; Have signed a written informed consent form.
Exclusion: They are currently participating in an interventional clinical trial, or have done so within the last 3 months before joining this study; Participants cannot join the study if:; They have a contraindication to cabozantinib treatment, based on the product's official prescribing information.